Deep Medicine Acquisition - Tradeable Rights - Oct 2026 Profit Margin

Deep Medicine Acquisition - Tradeable Rights - Oct 2026's profit margin stands at -75.66% as of March 2026. That compares with -45.71% in the prior-year period — down 65.5% year over year. That is below the sector sector average of 19.61%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Deep Medicine Acquisition - Tradeable Rights - Oct 2026 reported -75.66% in profit margin versus -45.71% a year earlier — a 65.5% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Deep Medicine Acquisition - Tradeable Rights - Oct 2026 sits lower the its sector benchmark (19.61%) with a profit margin of -75.66%. That is roughly 485.9% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of -75.66% for Deep Medicine Acquisition - Tradeable Rights - Oct 2026 means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Deep Medicine Acquisition - Tradeable Rights - Oct 2026's profit margin evolved across reporting periods, while the comparison chart places DMAQR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.